EcoDrugPlus

Integrin Beta-3-Like

Ensembl ID : ENSNBRG00000017506
Gene Symbol: LOC102787352
3 Cross references
194 Possible Orthologues:

Integrin Beta-5-Like

Ensembl ID : ENSNBRG00000014487
Gene Symbol: LOC102797011
3 Cross references
183 Possible Orthologues:

Integrin Subunit Alpha 4

Ensembl ID : ENSNBRG00000019511
Gene Symbol: ITGA4
3 Cross references
225 Possible Orthologues:

Integrin Subunit Beta 6

Ensembl ID : ENSNBRG00000020164
Gene Symbol: ITGB6
3 Cross references
206 Possible Orthologues:

Integrin Subunit Beta 8

Ensembl ID : ENSNBRG00000008722
Gene Symbol: ITGB8
1 Cross references
202 Possible Orthologues:

Interleukin-1 Receptor-Associated Kinase 4-Like

Ensembl ID : ENSNBRG00000019813
Gene Symbol: LOC102795705
3 Cross references
202 Possible Orthologues:

Intermediate Conductance Calcium-Activated Potassium Channel Protein 4-Like

Ensembl ID : ENSNBRG00000006378
Gene Symbol: LOC102793279
2 Cross references
187 Possible Orthologues:

Isocitrate Dehydrogenase [Nadp] Cytoplasmic-Like

Ensembl ID : ENSNBRG00000019389
Gene Symbol: LOC102790999
3 Cross references
232 Possible Orthologues:

Isocitrate Dehydrogenase [Nadp], Mitochondrial-Like

Ensembl ID : ENSNBRG00000000293
Gene Symbol: LOC102799818
3 Cross references
186 Possible Orthologues:

Isocitrate Dehydrogenase [Nadp], Mitochondrial-Like

Ensembl ID : ENSNBRG00000019851
Gene Symbol: LOC102794037
3 Cross references
207 Possible Orthologues:

Kappa-Type Opioid Receptor-Like

Ensembl ID : ENSNBRG00000009193
Gene Symbol: LOC102783796
3 Cross references
197 Possible Orthologues:

Kelch-Like Ech-Associated Protein 1-Like

Ensembl ID : ENSNBRG00000019129
Gene Symbol: LOC102796637
3 Cross references
189 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).